Letrozole Articles
Overview of Novartis' patent losses from GlobalData
11 October 2012
Aromatase inhibitors may increase risk of heart disease in postmenopausal women with breast cancer
10 December 2010
US FDA clears new uses for two GlaxoSmithKline drugs; Tykerb and Lamictal; GSK set to announce 3,000 job cuts
1 February 2010
Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes
26 January 2010
Novartis’ Femara “superior to tamoxifen in breast cancer”
20 August 2009
Novartis' 1st-qtr 2009 results boosted by new products
24 April 2009
GSK files to expand Tyverb use in USA & EU
3 April 2009
Novartis' Femara cuts risk of death post BC surgery
22 December 2008
Tyverk/Femara boost delay in progression
22 December 2008
Novartis profit up 32% in 3rd qtr
27 October 2008
Stock Commentary - Europe - week to Oct 13, 2008
20 October 2008
Zometa cuts risk of early-stage breast cancer recurrence
22 September 2008
Thai dispute over PReMA member for GPO board
5 May 2008
Femara cuts risk of breast cancer returning
17 March 2008
Foreign groups try to stop Thailand CL climbdown
3 March 2008
UK's NICE asked to develop new clinical health guidance for DoH
18 February 2008
Thailand Health Ministry change could mean fewer CLs
18 February 2008
UPDATE: Thailand negotiations on drug prices continue
29 October 2007
Thailand negotiations on drug prices continue
29 October 2007
Femara cuts metastatic recurrence in cancer
7 May 2007
Novartis' 1st-qtr 2007 profit up 11% to $2.17B on strong sales of cancer drugs and Diovan
30 April 2007
Aromatase inhibitors approved by UK's NICE
27 November 2006
Novartis sees 16% sales jump in first three qtrs of 2006 beating consensus estimates
30 October 2006
Israeli basket update c'tee recommends another 16 new technologies
4 September 2006
UK's NICE gives AI's tentative approval
29 May 2006
Novartis/Chugai launch Femara in Japan
22 May 2006
Scotland OKs Femara: rest of UK waits
15 May 2006
Japan stock market week to April 24, 2006
1 May 2006
Strong patient data for Novartis' Femara
3 April 2006
Wyeth to end Ph III temsirolimus trial
27 March 2006
Faslodex as advanced breast cancer drug
13 March 2006
Good results for Novartis' Femara
19 December 2005
UK OK for Femara in early breast cancer
12 December 2005
US FDA gives priority review to Novartis' Femara in new indication
5 September 2005
Stock Commentary - Europe - week to Aug 15
5 September 2005
Stock Commentary - Tokyo week to Aug 15
5 September 2005
Japan stock market two week to August 29
5 September 2005
NZ Pharmac gets budget boost, OKs new Rx uses
8 August 2005
Scotland OKs Femara, rejects other drugs
14 March 2005
Novartis' Femara gets new use in USA
8 November 2004
Femara available in UK for new use
20 September 2004
Stock Commentary - Europe
23 August 2004
Novartis' Femara gets Swiss OK for new use
16 August 2004
Stock Commentary - Europe
12 July 2004
Priority review for Femara sNDA
5 July 2004
Aromasin prolongs breast cancer survival
29 March 2004
Stock Commentary - Europe
20 October 2003
Novartis launches Femara in China
15 July 2002
Novartis Glivec works in early-stage CML
27 May 2002
Femara more effect than tamoxifen
7 January 2002
Femara more effect than tamoxifen
17 December 2001
Arimidex outdoes tamoxifen in study
13 December 2001
Stock Commentary - Europe
1 February 2001
EU appro for Novartis' Femara as first-line
26 January 2001
Femara approved for first-line use in USA
11 January 2001
FDA Committee backs Novartis' Femara
14 December 2000
Novartis R&D day updates prospects for key pipeline drugs
7 December 2000
Chugai interim net income rises 8.7%
30 November 2000
Novartis shows tamoxifen superiority with breast cancer drug Femara
29 September 2000
New Femara indication fast-tracked in USA
14 September 2000
Chugai shares downgraded on concerns over product pipeline
6 September 2000
Novartis says 25% chance Zelmac NDA will not be accepted
22 February 2000
Chugai reports recent filings and R&D pipeline
2 August 1999
Chugai Restructures For The 21st Century
28 August 1998
Zeneca Allays Fears Of Near-Term Product Gap
4 December 1997
Strong Advance In 1st-Half Profits At Novartis
29 August 1997
1st Approval For Novartis' Exelon; 2nd For Revasc
7 August 1997
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
